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Abstract
BACKGROUND: Multidrug chemotherapy increases the efficacy 
of the treatment, but at the same time rises its cardiotoxicity. The 
majority of cardiac complications are caused by anthracyclines. 
Radiation therapy may intensify cardiotoxicity. The aim of this 
study was to determine early changes of cardiac function using 
radionuclide ventriculography in patients with breast cancer and 
to compare the toxicity of AC and AT chemotherapy programs. 
MATERIAL AND METHODS: The study included 71 patients 
with breast cancer between the ages of 38 and 71 years. All 
patients after surgery were qualified for chemotherapy, and for 
37 (52%) of them subsequent irradiation treatment was planned. 
Patients received chemotherapy according to the scheme: AC 
— 47 patients (66%) and AT — 24 patients (34%). Patients were 
irradiated using a photon beam (4 to 6 MeV) and an electron 
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beam (6–15 MeV). In all patients, before and six months after 
the treatment, radionuclide ventriculography was performed. 
RESULTS: In all 71 patients a reductions in left ventricular 
ejection fraction (EF) and in peak filling rate (PFR) as well as 
an increase in the end-systolic and end-diastolic volumes (ESvol, 
EDvol) were observed. AC chemotherapy, where cumulative 
anthracycline dose was higher, significantly decreased left 
ventricular ejection fraction and PFR and increased ESvol. After 
AT chemotherapy the  EF reduction proved to be smaller. Radio-
therapy did not significantly lower the value of EF as compared 
to the group of patients who underwent chemotherapy. 
CONCLUSIONS: Radionuclide ventriculography is a useful 
method of evaluating the cardiotoxicity of the treatment. Early 
indicators of myocardial damage are EF, PFR, ESvol and EDvol. 
AC chemotherapy, where the average cumulative dose of an-
thracyclines was higher, caused more cardiotoxic effects than 
AT chemotherapy.
Applying additional radiotherapy did not significantly increase 
the cardiotoxicity of the treatment.
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Introduction
Multidrug chemotherapy used in variety of cancers increas-
es the effectiveness of the treatment, but is also associated with 
toxicity, including cardiotoxicity. The majority of cardiac complica-
tions is caused by anthracyclines, regarded as one of the most 
effective anti-tumor agents. Anthracycline-induced cardiotoxicity 
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is directly related to the cumulative dose of anthracyclines received, 
and is irreversible [1].
Radiation-induced heart disease includes coronary artery 
disease, valvular disease, constructive pericarditis and myocardial 
dysfunction [2]. Radiotherapy is often associated with late, deve-
loping over the years, side effects. First cardiac complications oc-
cur within 12 to 24 months after the treatment [3]. Combination 
therapy — chemoradiotherapy may intensify the toxicity of both 
methods of cancer therapy.
Nowadays, the problem of cardiotoxicity is particularly im-
portant due to the effectiveness of oncological treatment in some 
patients, resulting in long-term remission or overall survival. Drug- 
and radiation-induced damage to the heart can lead to congestive 
heart failure, and as a result significantly limit and impede the 
normal functioning of the patient.
Echocardiography is commonly used to monitor cardiac 
complications of cancer therapy. It is a non-invasive and widely 
available method, that provides valuable information about systolic 
and diastolic left ventricular function, morphological changes in 
cardiac structures and the degree of hemodynamic changes [4]. 
However, in many patients after therapy, postsurgery or postradia-
tion changes impede or even prevent the execution or interpreta-
tion of the study.
Radionuclide ventriculography is a noninvasive, useful method 
for the quantitative measurement of the left ventricular function and 
the assessment of the regional wall motion [5]. 
The aim of this study was to determine early changes in 
cardiac function using radionuclide ventriculography in pa-
tients with breast cancer after chemotherapy and chemoradio-
therapy and to compare the toxicity of AC and AT chemotherapy 
regimens.
Material and methods
The study included 71 patients with breast cancer between 
the ages of 38 and 71 (mean — 54; median — 53 years). All 
patients that underwent surgery (mastectomy) were qualified for 
adjuvant chemotherapy.
Patients received chemotherapy according to the schemes:
 — AC [adriamycin (ADM) 60 mg/m2 i.v. and cyclophosphamide 
(CTX) 600 mg/m2 i.v. — every 3 weeks]. Patients received 
from 4 to 8 courses;
 — AT [adriamycin (ADM) 50–60 mg/m2 i.v. and docetaksel 
70 mg/m2 (15 patients) or paclitaxel 175 mg/m2 (9 patients) — every 
3 weeks]. Patients received from 4 to 6 courses (Table 1). 
Of the 71 patients who underwent chemotherapy or combined 
therapy:
 — 47 (66%) were treated according to the AC regimen, with 22 
(47%) qualified for radiotherapy;
 — 24 (34%) were treated according to the AT regimen, with 15 
(62%) qualified for radiotherapy.
Of all 71 patients after AC or AT chemotherapy 37 (52%) under-
went radiotherapy. In this group in 19 (51%) patients tumor was lo-
cated in the right breast and in 18 (49%) patients in the left breast.
Patients were irradiated using a photon beam with an energy 
range from 4 to 6 MeV and the electrons beam with an energy 
6–15 MeV in one, two or three of the following fields:
 — field of scar + parasternal lymph nodes — irradiated with 
electrons beam individually matched to the thickness of the 
chest wall, in a fractional dose of 200–225 cGy/90% to a total 
dose of 5000 or 4500 cGy/90%;
 — supraclavicular field — irradiated with photon X (4–6 MeV) 
in a fractional dose of 200–225 cGy to a total dose of 5000 
cGy or 4500;
 — posterior axillar field — irradiated with photon X (4–6 MeV) to 
a total dose of 4500 cGy or 5000 calculated in the middle of 
the armpit.
Study protocol
Scintigraphic examination was performed using the in vivo 
method of red blood cells labeled with 99mTc. 20 minutes after stan-
nous (II) chloride injection patients received intravenously 740–925 
MBq (20 - 25 mCi) 99mTc pertechnetate (99mTcO4).
Gated acquisition was performed using dual-head gam-
ma-camera, with low-energy and high resolution collimator (LEHR), 
30 minutes after the administration of radiopharmaceutical. The 
energy analyzer was set to 140 keV and the width of the energy 
window was ± 10%.
Images were obtained using the left anterior oblique projec-
tion 45° (LAO 45) in order to better separate the chambers of the 
heart. Additionally, 10–15° caudal tilt was applied to separate left 
atrium from left ventricle [6]. Computer reconstruction of the image 
was made 2–3 times using a semi-automatic method.
In the study the following parameters were assessed: ejection 
fraction (EF); peak filling rate (PFR); peak ejection rate (PER); 
end-diastolic volume (EDvol); end-systolic volume (ESvol).
In all post-surgery patients radionuclide ventriculography 
was performed before and six months after chemo- and chemo-
radiotherapy. 
Statistical analysis 
The statistical analysis of the results was made using the 
computer program STATISTICA Version 8. All values are expressed 
as the mean + SD. Student’s test was used for comparison 
between baseline and post treatment values in each group and 
a p value < 0.05 was considered statistically significant. In cases of 
distribution other than normal the Mann-Whitney test was used. 
Correlation of normally distributed variables with equal vari-
ances was evaluated using Pearson’s correlation coefficient and 
in cases of distribution other than normal with Spearman’s coef-
ficient. The data were also assessed using a multivariate analysis of 
variance (MANOVA).
Table 1. Average cumulative dose of anthracyclines received by patients in each group [mg/m2]
Whole group ACtotal AC (only) AC + rth ATtotal AT (only) AT + rth
ADM dose 375 395 390 400 330 340 320
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Half year after the treatment in all 71 patients a decrease of 
ejection fraction (EF) from 63% to 60% and a reduction of peak 
filling rate (PFR) from 4.78 to 4.44 vol/s were observed. Moreo-
ver, end-systolic volume (ESvol) increased from 20 to 24 ml and 
end-diastolic volume (EDvol) from 55 to 59 ml (Figure 1). 
In patients after AC chemotherapy (n = 47, including 22 pa-
tients additionally subjected to radiotherapy), significant reduction 
in EF and PFR as well as increase in ESvol were found.
In patients after AT chemotherapy (n = 24, including 15 pa-
tients who received rth), there was also a significant decrease in 
EF, but it was smaller than in AC arm. Moreover, ESvol and EDvol 
an increase and PFR reduction were observed.
However, it should be noted that the cumulative dose of 
anthracyclines in the group of patients treated according to AC 
chemotherapy was significantly higher than in patients treated with 
AT chemotherapy (390 mg/m2 vs. 330 mg/m2) (Table 2).
Additional radiotherapy in 37 patients after AC or AT chemo-
therapy did not significantly decrease EF compared to 34 pa-
tients who received only chemotherapy. 
However, in patients with left-sided irradiation lower EF and 
an increase in ESvol were observed as opposed to patients with 
right-sided irradiation (Table 3, Figure 1).
Additionally, a correlation between the cumulative dose of 
the drug and the reduction of PFR was found — the higher the 
cumulative dose of anthracycline, the lower the PFR. What is more, 
a connection between a higher radiation dose and an increased 
EDvol as well as a higher radiation dose and a decreased PFR 
was observed. 
Discussion
Cardiotoxic effects of chemotherapy  
in women with breast cancer
Our study, carried out before and 6 months after the treat-
ment, has demonstrated an adverse effect of chemotherapy 
and combined treatment — chemoradiotherapy in the group of 
patients with breast cancer.
As a result of the treatment in all patients both abnormal 
systolic and diastolic left ventricular function were found. A sig-
nificant reduction in EF and PFR as well as an increase in ESvol 
and EDvol were noted.
According to some authors, in patients treated with anthracy-
clines, despite the absence of cardiac clinical signs and cardiac 
changes visible on echocardiography, early left ventricular diastolic 
dysfunction was observed. That may indicate that diastolic dys-
function is an early marker for anthracycline cardiotoxicity [7–9].
Massing et al [10] in their evaluation of the toxicity of anthra-
cyclines, in a short period of time (4 weeks after the treatment), 
noted a significant decrease in the maximal velocity of early dias-
tolic filling time, as well as a less significant decrease in ejection 
fraction. Suzuki et al. [11] assessing the cardiac function 2 and 
4 weeks after the administration of anthracyclines also have not 
observed any significant change in EF, whereas diastolic para-
meters such as the initial 1/3 of peak filling rate corrected by the 
end-diastolic count (1/3 PFR/EDC) and the initial 1/3 of the filling 
fraction (1/3 FF) decreased significantly.
However, in the literature there are reports showing that even 
in the early period after chemotherapy both systolic and diastolic 
parameters change.
Table 2. Haemodynamic parameters with significant changes 6 months after the treatment, as compared to baseline values (changes in 
other parameters showed no statistical significance NS)
ACtotal group (n = 47) ATtotal group (n = 24)
Before After p Before After p
EF 62.7 ± 4.4 59.5 ± 6.1 P < 0.004 EF 63.7 ± 5.2 61.7 ± 5.3 P < 0.028
PFR 4.7 ± 1.6 4.3 ± 1.0 P < 0.016 ESvol 17.5 ± 7.1 21.5 ± 7.9 P < 0.012
ESvol 21.6 ± 7.9 24.9 ± 9.9 P < 0.09 EDvol 48.5 ± 16.4 56.3 ± 17.2 P < 0.043
Table 3. Comparison of changes in EF in patients irradiated for the 
left and right sides 6 months after the treatment
Before After p
Right side 63.5 ± 4.2 62 ± 4.1 NS
Left side 62.5 ± 5.2 58.5 ± 6.9 P < 0.001
Figure 1 Hemodynamic parameters with significant changes 6 months 
after the treatment, as compared to baseline values. 
Figure 2. Graphic representation of significant changes in haemody-
namic parameters 6 months after the treatment.
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fraction and the presence of pre-existing cardiovascular risk fac-
tors [19]. Patients treated with radiation therapy during 1970–1985 
for left-sided breast cancer were found to have a higher mortality 
rate, due to myocardial infarction, than patients with right-side 
tumours [20]. 
It may seem that the reason for such high risk of heart da-
mage was mainly due to deficiencies of planning and treatment 
techniques used in those times. 
The type of radiotherapy proved to be significant in the devel-
opment of cardiac complications. In the study 37 patients were 
irradiated using a photon beam with an energy range from 4–6 MeV 
and electrons with an energy of 6–15 MeV in fractional doses to 
a maximum dose of 50 Gy. 
Megavoltage therapy, used currently, is less harmful for the 
body than the conventional X-rays therapy (with an energy of 
250 kV). New techniques such as three-dimensional treatment 
planning and improved dosimetric planning are associated with 
lower cardiac morbidity [21]. Computerized three-dimensional 
treatment planning system (3D) allows to customize the type and 
dose of radiation to the patient’s anatomy and the size and shape 
of the irradiated area [22]. This can also explain why in our study 
in patients, who underwent radiotherapy, no significant decrease 
in the evaluated parameters was noted.
Rutqvist et al. [23] found no indication of increased risk of 
acute myocardial infarction in the group of 684 patients after 
mastectomy and radiotherapy, which was given with tangential 
photon fields (total dose 48–52 Gy, given with 2 Gy daily fraction) 
in comparison with 4996 patients treated with mastectomy.
Monitoring of cardiotoxicity of antineoplastic agents (particu-
larly anthracyclines) should be included in the strategic treatment 
planning for most patients. The appearance of early indicators of 
myocardial damage allows rapid intervention, modification of 
the treatment, inclusion of cardioprotective treatment as well 
as cardiac supervision in this group of patients. This is especially 
important with a positive prognosis on the length of survival after 
the treatment. 
Nowadays, it is recommended to perform the baseline radio-
nuclide venticulography in patients admitted to anthracycline-con-
taining chemotherapy, and then to control the EF after a cumula-
tive dose of 400 mg/m2 in patients with known heart disease or 
450 mg/m2 in patients without this risk factor. In patients whose 
EF declines below 50% or decreases 10% of its baseline value 
a change of the treatment regimen is recommended [24]. 
Conclusions
Our Findings confirm that already in the early period after 
chemotherapy the cardiotoxic effects of the treatment using 
non-invasive method such as radionuclide ventriculography can 
be assessed.
Among early indicators of myocardial damage are primarily ejec-
tion fraction and peak filling rate and, to a lesser extent, end-systolic 
and end-diastolic volume of the left ventricular function.
Chemotherapy according to the AC regimen, where the mean 
cumulative anthracycline dose was higher, proved to cause more 
cardiotoxic effects than AT chemotherapy.
The additional use of radiotherapy did not significantly increase 
the cardiotoxicity of the antitumor therapy. 
Cottin and colleagues [12], in their work conducted on a group 
of 60 patients treated with anthracycline-containing chemotherapy, 
observed a significant decrease in ejection fraction, PFR and 
PER already one month after the treatment. They came to the 
conclusion that both systolic and diastolic left ventricular function 
parameters are subject to early changes after the treatment.
In our study, changes of systolic and diastolic parameters were 
noted after six-months observation period, even though the 
patients had no symptoms of heart failure. As in the case of 
anthracycline-induced myocardial damage clinical symptoms of 
heart failure usually develop over a period of several years follo-
wing the treatment [13]. It may be expected that in at least part of 
all patients heart failure will develop over the years.
We evaluated cardiotoxic effect of two regimens of anthra-
cycline-containing chemotherapy — AC and AT. In the AC group 
the average cumulative dose of the drug was 395 mg/m2, and 
thus was higher than in the AT group — 330 mg/m2. Radionuclide 
ventriculography 6 months after the treatment showed a reduction 
of ejection fraction in both groups, but the decrease was higher 
in the AC group, which confirms the dependence of cardiotoxicity 
on the cumulative dose of anthracyclines.
It is worth mentioning that paclitaxel and cyclophosphamide 
used in the treatment of breast cancer can also have toxic ef-
fects on the myocardium. 
In another study, carried out by Gehl et al. [14], 30 patients with 
advanced breast cancer underwent adjuvant combined chemo-
therapy (doxorubicin — 369 mg/m2 and paclitaxel). Although the 
anthracycline dose did not exceed the acceptable values a de-
crease of ejection fraction of left ventricular below normal levels in 
50% of all patients was noted, while 20% of all patients developed 
congestive heart failure. Other studies have also demonstrated 
that the combination of paclitaxel with doxorubicin intensifies the 
cardiotoxicity of the treatment [15, 16]. 
After 6 months of observation, no evidence of significant ad-
verse effects of irradiation on the parameters of the left ventricle 
function were found in comparison with the group of patients who 
were subjected only to chemotherapy. What proves to be inte-
resting, is that many previous studies proved that radiotherapy 
intensifies cardiotoxic effect of chemotherapy [17].
However, the group of patients with left-side chest-wall irradia-
tion, as compared to patients with right-side irradiation, showed 
a significant reduction in ejection fraction and an increase in 
end-systolic volume of left ventricle.
Cardiotoxicity of chemoradiotherapy  
in patients with breast cancer
Radiation therapy is often associated with late complica-
tions remaining silent for several years. In the initial period after 
the radiotherapy the cardiac dysfunction triggers compensatory 
mechanisms. Sympathetic nervous system stimulation prevents de-
terioration of myocardial function [18]. This mechanism may explain 
why in our study there was no significant change in the ejection 
fraction in patients who additionally underwent radiotherapy. Only 
reduced peak filling rate (PFR) and increased end-systolic volume 
(ESvol) were observed in patients after AC chemotherapy, which 
may indicate future development of cardiac dysfunction. 
Complications after radiotherapy may depend on several fac-
tors, including the irradiated heart volume, total irradiation dose per 
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